17 Nov 2022 Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection
17 Nov 2022 Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02
17 Nov 2022 Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines
15 Nov 2022 Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an 'off-the shelf' Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer
15 Nov 2022 Daiichi Sankyo Announces Results of Booster Vaccination Trial of Its mRNA COVID-19 Vaccine (DS-5670) in Japan
12 Nov 2022 YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 vaccine
10 Nov 2022 New Inventprise Pneumococcal Vaccine Enters Phase 1/2 Clinical Evaluation
10 Nov 2022 Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
08 Nov 2022 Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine (HexaPro) Delivered Using High-Density Microarray Patch (HD-MAP)
07 Nov 2022 Blue Lake Biotechnology Announces Positive Interim Phase 1 Data for BLB201 Intranasal RSV Vaccine
07 Nov 2022 Meissa Vaccines Announces Positive Interim Clinical Data for Its Intranasal Live Attenuated Respiratory Syncytial Virus (RSV) Vaccine Candidate for Infants
07 Nov 2022 Geneos Therapeutics Announces Positive Clinical Data for Personalized Therapeutic Cancer Vaccines in Ongoing Liver Cancer Trial
05 Nov 2022 Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
04 Nov 2022 Positive results from AELIX’ HIV therapeutic vaccine clinical study published in Nature Medicine
02 Nov 2022 Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
01 Nov 2022 Akston Biosciences Announces Positive Interim Phase II Results from COVID “Universal” Booster Vaccine Trial
01 Nov 2022 Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
01 Nov 2022 Vaccitech Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 immunotherapeutic candidate for Chronic HBV Patients
01 Nov 2022 Vaxzevria receives full Marketing Authorisation in the EU for the prevention of COVID-19
27 Oct 2022 Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1/2a Study of VB10.NEO, an Individualized Therapeutic Cancer Vaccine, at the Neoantigen-Based Therapies Summit
26 Oct 2022 Codagenix Initiates Dosing in Phase 3 Efficacy Trial of Intranasal COVID-19 Vaccine as Part of WHO-Sponsored Solidarity Trial Vaccines
26 Oct 2022 Gritstone Presents Positive Results from Two Phase 1 CORAL Studies, Providing Further Proof-of-Concept for Self-amplifying mRNA (samRNA) in Infectious Diseases
26 Oct 2022 SK bioscience and CEPI Sign Agreement to Develop mRNA Vaccines
24 Oct 2022 Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
20 Oct 2022 Everest Medicines Announces Partner Providence Reports Positive Top-Line Data from Phase 2 Primary Immunization Trial for mRNA COVID-19 Vaccine Candidate in Adults

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up